Evaluating the Treatment with Favipiravir in Patients Infected by COVID-19: A Systematic Review and Meta-analysis

Document Type : Review Article


1 School of Medicine, Capital Medical University, Beijing, China

2 Department of Internal Medicine, School of Medicine, Shahid Mohammadi Hospital, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

3 Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

4 School of Medicine, Guilan University of Medical Sciences, Rasht, Iran

5 Department of Internal Medicine, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran


Background and aim: Considering the results of studies and the potential of using favipiravir treatment of COVID-19, reviewing the results of clinical trial studies and summarizing the results are of great importance. It may be possible to use favipiravir extensively in the future. Therefore, the purpose of the present systematic review and meta-analysis was to evaluate the improvement rates of favipiravir treatment in patients with COVID-19.
Materials and methods: From the electronic databases, PubMed, Cochrane Library, Embase, ISI have been used to perform systematic literature between 2010 and 2020. Therefore, a software program (Endnote X8) has been utilized for managing electronic titles. Searches were performed with mesh terms. The odds ratio between the two groups (Favipiravir and control) with a 95% confidence interval was calculated. Random effects were used to deal with potential heterogeneity, and I2 showed heterogeneity. The Meta-analysis and forest plots have been evaluated using a software program available in the market (i.e., Comprehensive Meta-Analysis Stata V16).
Results: According to the research design, 186 potentially important research abstracts and titles have been discovered in our electronic searches. Finally, two papers remained in agreement with our inclusion criteria required. Statistically, a significant difference observed between improvement rates of the Favipiravir group and control group (p=0.01).
Conclusion: Positive effect and improvement rates of favipiravir VS control groups observed to treat patients with COVID-19.


Main Subjects

[1]  Schwartz DA, Graham AL. Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections. Viruses. 2020;12(2):194. https://doi.org/10.3390/v12020194.
[2]  Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). InStatpearls [internet] 2020. StatPearls Publishing.
[3]  Borges do Nascimento IJ, Cacic N, Abdulazeem HM, von Groote TC, Jayarajah U, Weerasekara I, Esfahani MA, Civile VT, Marusic A, Jeroncic A, Carvas Junior N. Novel coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis. Journal of clinical medicine. 2020;9(4):941. https://doi.org/10.3390/jcm9040941.
[4]  (CSSE) CfSSaE. global statistics of COVID-19 2020.
[5]  Li H, Liu Z, Ge J. Scientific research progress of COVID‐19/SARS‐CoV‐2 in the first five months. Journal of cellular and molecular medicine. 2020;24(12): 6558-70. https://doi.org/10.1111/jcmm.15364.
[6]  Sohrabi C, Alsafi Z, O’Neill N, Khan M, Kerwan A, Al-Jabir A, Iosifidis C, Agha R. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). International Journal of Surgery. 2020;76:71-76. https://doi.org/10.1016/j.ijsu.2020.02.034.
[7]  Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020;323(13):1239-42. doi:10.1001/jama.2020.2648.
[8]  Ather A, Patel B, Ruparel NB, Diogenes A, Hargreaves KM. Coronavirus disease 19 (COVID-19): implications for clinical dental care. Journal of endodontics. 2020;46(5):584-95. https://doi.org/10.1016/j.joen.2020.03.008.
[9]  Kalil AC. Treating COVID-19—off-label drug use, compassionate use, and randomized clinical trials during pandemics. Jama. 2020;323(19):1897-8. doi:10.1001/jama.2020.4742.
[10] Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir–a potential treatment in the COVID-19 pandemic?. Journal of Virus Eradication. 2020;6(2):45.
[11] Mitjà O, Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. The Lancet Global Health. 2020;8(5):e639-40. https://doi.org/10.1016/S2214-109X(20)30114-5.
[12] Xuan Y. Initial clinical results announced for favipiravir treatment of novel coronavirus pneumonia-viral clearance in four days. Biodiscover. 2020.
[13] Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, Chen B, Lu M, Luo Y, Zhang J, Yin P. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv. 2020.
[14] Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, Atkins D, Barbour V, Barrowman N, Berlin JA, Clark J. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement (Chinese edition). Journal of Chinese Integrative Medicine. 2009;7(9):889-96. 10.3736/jcim20090918.
[15] Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928.
[16] Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y, Shen C. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020. https://doi.org/10.1016/j.eng.2020.03.007.
[17] Kikuchi G, Motokawa Y, Yoshida T, Hiraga K. Glycine cleavage system: reaction mechanism, physiological significance, and hyperglycinemia. Proceedings of the Japan Academy, Series B. 2008;84(7):246-63. https://doi.org/10.2183/pjab.84.246.
[18] De Clercq E. New nucleoside analogues for the treatment of hemorrhagic fever virus infections. Chemistry–An Asian Journal. 2019;14(22):3962-8. https://doi.org/10.1002/asia.201900841.
[19] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell research. 2020;30(3):269-71. https://doi.org/10.1038/s41422-020-0282-0.
[20] Wu R, Wang L, Kuo HC, Shannar A, Peter R, Chou PJ, Li S, Hudlikar R, Liu X, Liu Z, Poiani GJ. An update on current therapeutic drugs treating COVID-19. Current Pharmacology Reports. 2020;6:56–70. https://doi.org/10.1007/s40495-020-00216-7.
[21] Arab-Zozani M, Hassanipour S, GHoddoosi-Nejad D. Favipiravir for treating novel coronavirus (COVID-19) patients: protocol for a systematic review and meta-analysis of controlled trials. medRxiv. 2020.
Volume 2, Issue 3
September 2020
Pages 87-91
  • Receive Date: 04 May 2020
  • Revise Date: 25 July 2020
  • Accept Date: 05 August 2020
  • First Publish Date: 01 September 2020